ClinicalTrials.gg
CompletedNCT07680686Updated Nov 13, 2026

Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants

A Phase 1 interventional study of Ubrogepant and Ubrogepant in Healthy Volunteer, sponsored by AbbVie. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

Updated Nov 13, 2026Now CompletedNow Active, not recruiting+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will assess how different oral formulations of ubrogepant move through the body in healthy adult participants under fasting and fed conditions.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Volunteer
  • Ubrogepant
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead .

Exclusion criteria

Exclusion Criteria:

  • History: of epilepsy, any cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic, neurologic, or psychiatric disease or disorder, history of Raynaud's Phenomenon, or any uncontrolled medical illness.
  • History of any clinically significant sensitivity or allergy to any medication or food.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Ubrogepant-Part 1-Dose A

    Participants will receive a single oral dose A of ubrogepant on Day 1 under fasting conditions.

    Drug: Ubrogepant

  • Experimental
    Ubrogepant-Part 1-Dose B

    Participants will receive a single oral dose B of ubrogepant on Day 1 under fasting conditions.

    Drug: Ubrogepant

  • Experimental
    Ubrogepant-Part 2-Dose C

    Participants will receive a single oral dose C of ubrogepant on Day 1 under fasting conditions.

    Drug: Ubrogepant

  • Experimental
    Ubrogepant-Part 2-Dose D

    Participants will receive a single oral dose D of ubrogepant on Day 1 under fed conditions.

    Drug: Ubrogepant

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events

    An adverse event is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 33 days

  2. Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCt) of Ubrogepant

    AUCt of Ubrogepant

    Time frame: Up to approximately 3 days

  3. AUC From Time 0 to the Time Infinity (AUCinf) of Ubrogepant

    AUCinf of Ubrogepant

    Time frame: Up to approximately 3 days

  4. Maximum Observed Plasma Concentration (Cmax) of Ubrogepant

    Cmax of Ubrogepant

    Time frame: Up to approximately 3 days

  5. Time lag between dosing and drug to appear in systemic circulation following extravascular administration (Tlag) of Ubrogepant

    Tlag of Ubrogepant

    Time frame: Up to approximately 3 days

  6. Time to maximum observed plasma concentration (Tmax) of Ubrogepant

    Tmax of Ubrogepant

    Time frame: Up to approximately 3 days

  7. Apparent terminal phase elimination constant (λz) of Ubrogepant

    λz of Ubrogepant

    Time frame: Up to approximately 3 days

  8. Terminal phase elimination half-life (t1/2) of Ubrogepant

    t1/2 of Ubrogepant

    Time frame: Up to approximately 3 days

  9. Apparent total body clearance of drug from plasma after extravascular administration (CL/F) of Ubrogepant

    CL/F of Ubrogepant

    Time frame: Up to approximately 3 days

  10. Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of Ubrogepant

    Vz/F of Ubrogepant

    Time frame: Up to approximately 3 days

07

Study locations

1 site
  • Acpru /Id# 282727
    Grayslake, Illinois 60030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2026 to primary completion in Oct 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Jul 2, 2026
StartActual
Jul 14, 2026
Primary completionActual
Oct 16, 2026
CompletionActual
Oct 16, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting→Completed
changed Oct 13, 2026 · changed Nov 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    Active, not recruiting→Completed
    + 2 other changes: verification date and date precision
  2. Oct 13, 2026
    Recruiting→Active, not recruiting
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07680686
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Jul 14, 2026
Primary completion
Oct 16, 2026
Completion
Oct 16, 2026
Last update
Nov 13, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ubrogepant

Start the discussion